Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Circulatory Exercise After Total Knee Replacement

3 juillet 2026 mis à jour par: Mariam ibrahim, Assiut University

Boosting Venous Return After Knee Replacement: Effects of a Novel Circulatory Exercise on Early Postoperative Inflammation - A Randomized Controlled Trial

Total knee replacement is commonly associated with early postoperative inflammation, edema, pain, and reduced mobility. This randomized controlled trial will evaluate whether adding a simple circulatory exercise program to standard postoperative rehabilitation reduces early limb edema and inflammatory response after unilateral primary total knee replacement. Participants will be randomized to standard rehabilitation alone or standard rehabilitation plus seated and supine knee-extension exercises with alternating ankle dorsiflexion. The primary endpoint is change in limb edema measured by standardized limb circumference at postoperative day 14.

Aperçu de l'étude

Description détaillée

This is a randomized, parallel-group, assessor-blinded controlled clinical trial. Adults undergoing elective unilateral primary total knee replacement for osteoarthritis will be allocated in a 1:1 ratio to either standard postoperative rehabilitation or standard rehabilitation plus a circulatory exercise protocol. The intervention includes supine leg elevation with ankle pump and knee extension, and seated knee extension with alternating ankle dorsiflexion. The exercise will be performed at approximately 15 cycles per minute, 10 sets of 1 minute, with 60 seconds rest between sets, twice daily for 14 postoperative days. Outcomes include limb circumference, pain, functional mobility, quadriceps strength, inflammatory biomarkers, hemostasis markers, analgesic use, patient satisfaction, and adverse events.

Type d'étude

Interventionnel

Inscription (Estimé)

68

Phase

  • N'est pas applicable

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Adults ≥ 18 years undergoing elective unilateral primary TKR for osteoarthritis.
  • Able to provide informed consent.
  • Able to perform the exercise (cognitively and physically) prior to discharge.

Exclusion Criteria:

  • Preexisting peripheral vascular disease with severe ischemia or venous insufficiency that limits exercise.
  • Contraindication to early active movement per surgeon (e.g., complex surgical fixation limiting motion if present).
  • Severe neurological or cognitive impairment preventing instruction adherence.
  • Inability to comply with follow-up.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: standard postoperative TKR rehabilitation (hospital protocol)
Participants will receive standard postoperative total knee replacement rehabilitation according to the local hospital protocol, including early mobilization, ROM exercises, quadriceps activation, ambulation training, and standard pain/edema management as clinically indicated.
Expérimental: Circulatory Exercise Protocol (in addition to standard rehab)
Participants will receive standard postoperative rehabilitation plus a circulatory exercise protocol including supine leg elevation with ankle pump and knee extension, and seated knee extension with alternating ankle dorsiflexion. The exercise will be performed at approximately 15 cycles/minute, 10 sets of 1 minute, 60 seconds rest between sets, twice daily for 14 postoperative days.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Difference in postoperative lower-limb edema between the operated and contralateral limbs measured by standardized limb circumference (cm)
Délai: Baseline/preoperative to postoperative day 14
Lower-limb circumference (cm) will be measured bilaterally at standardized anatomical landmarks: 10 cm above the superior border of the patella, at the mid-patellar level, and 20 cm above the superior border of the patella. Measurements will be obtained on both the postoperative limb and the contralateral (sound) limb. Edema will be quantified as the side-to-side difference in circumference and the change from baseline.
Baseline/preoperative to postoperative day 14

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Postoperative pain intensity measured by the Numeric Rating Scale (NRS, 0-10) at rest and during activity
Délai: Baseline/preoperative to postoperative day 14
Pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Scores will be recorded at rest and during activity.
Baseline/preoperative to postoperative day 14
Functional mobility:
Délai: Baseline/preoperative to postoperative day 14

Timed Up and Go (TUG) (go for 3 meter and come back). Record assistance level and gait aids.

3-meter walk test at regular base and fast base.

Baseline/preoperative to postoperative day 14
Analgesic consumption
Délai: Baseline/preoperative to postoperative day 14
Opioid consumption: record rescue analgesic use
Baseline/preoperative to postoperative day 14
Quadriceps strength via handheld dynamometry.
Délai: Baseline/preoperative to postoperative day 14

Seated 60 Degrees Knee Flexion Patient position Seated on the edge of the table, with feet not in contact with the ground and knee at 60 degrees of flexion.

Contact point Posterior aspect of the ankle attachment, at the hook closest to the achilles tendon.

Device orientation Horizontal, linked to the ankle strap at one end and anchored to a fixed surface by the cable strap at the other, posterior to the patient's leg being tested.

Position of examiner Adjacent to the patient, in a position to situate the DynaMo and instruct the action.

Instruction Pull against the DynaMo as hard as you can. 3, 2, 1 - pull, pull, pull and relax.

Attachments Tension links, Carabiners, Ankle strap, Tension strap.

Baseline/preoperative to postoperative day 14
Neuromuscular electrical stimulation response
Délai: Baseline/preoperative to postoperative day 14
Neuromuscular electrical stimulation response by chattanoga multi-current electrical stimulation.
Baseline/preoperative to postoperative day 14
Patient satisfaction with postoperative recovery measured by a 5-point Likert Scale
Délai: postoperative day 14
Patient satisfaction with postoperative recovery will be assessed on postoperative day 14 using a 5-point Likert Scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, and 5 = very satisfied.
postoperative day 14
Serum Interleukin-6 (IL-6)
Délai: Baseline (pre-operative), 24-48 hours post-operative (peak IL-6 window), Baseline/preoperative to postoperative day 14.

Interleukin-6 is a pro-inflammatory cytokine and an early mediator of the surgical stress response. Serum IL-6 will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater systemic inflammatory response; IL-6 peaks at approximately 24-48 hours postoperatively.

Unit: pg/mL · Reference: < 7 pg/mL (assay-dependent)

Baseline (pre-operative), 24-48 hours post-operative (peak IL-6 window), Baseline/preoperative to postoperative day 14.
Hemostasis or clotting tests
Délai: Baseline/preoperative to postoperative day 14
PT (Prothrombin Time) APTT (Activated Partial Thromboplastin Time) D-dimer Fibrinogen
Baseline/preoperative to postoperative day 14
Serum C-Reactive Protein (CRP)
Délai: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.

C-reactive protein is a hepatically synthesized acute-phase reactant produced in response to IL-6 signaling. Serum CRP will be measured from peripheral venous blood by immunoturbidimetric assay. Higher concentrations indicate greater systemic inflammation; CRP peaks later than IL-6 (~48-72 hours).

Unit: mg/L · Reference: < 10 mg/L (hs-CRP: < 1 low, 1-3 moderate, > 3 high cardiovascular risk)

Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
Serum Interleukin-10 (IL-10)
Délai: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.

Interleukin-10 is an anti-inflammatory cytokine mediating the compensatory anti-inflammatory response to surgical injury. Serum IL-10 will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater compensatory anti-inflammatory response.

Unit: pg/mL · Reference: < 10 pg/mL (often < 5 pg/mL; assay-dependent)

Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
Serum Tumor Necrosis Factor-alpha (TNF-α)
Délai: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.

Tumor necrosis factor-alpha is a pro-inflammatory cytokine released early in the innate immune response to tissue injury. Serum TNF-α will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater pro-inflammatory response.

Unit: pg/mL · Reference: < 8.1 pg/mL (commonly < 15-20 pg/mL; assay-dependent)

Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
Prothrombin Time (PT)
Délai: Baseline (preoperative) and postoperative day 14.

Prothrombin time assesses the extrinsic and common coagulation pathways. PT will be determined on platelet-poor plasma (peripheral venous blood in 3.2% sodium citrate) by an automated clot-based method using a thromboplastin reagent. A prolonged PT indicates impaired extrinsic/common-pathway function.

Unit: seconds · Reference: 11-13.5 seconds (INR 0.8-1.1)

Baseline (preoperative) and postoperative day 14.
Activated Partial Thromboplastin Time (APTT)
Délai: Baseline (preoperative) and postoperative day 14.

Activated partial thromboplastin time assesses the intrinsic and common coagulation pathways. APTT will be determined on citrated platelet-poor plasma by an automated clot-based method. A prolonged APTT indicates impaired intrinsic/common-pathway function.

Unit: seconds · Reference: 25-35 seconds

Baseline (preoperative) and postoperative day 14.
D-dimer
Délai: Frame: Baseline (preoperative) and postoperative day 14.

D-dimer is a fibrin degradation product reflecting activation of coagulation and fibrinolysis. D-dimer will be measured on citrated plasma by a latex-enhanced immunoturbidimetric assay. Elevated concentrations indicate increased fibrin turnover (hypercoagulable/prothrombotic state or venous thromboembolism).

Unit: µg/mL FEU · Reference: < 0.50 µg/mL FEU (< 500 ng/mL FEU)

Frame: Baseline (preoperative) and postoperative day 14.
Fibrinogen
Délai: Baseline (preoperative) and postoperative day 14.

Fibrinogen (coagulation factor I) is the soluble precursor of fibrin and an acute-phase reactant. Plasma fibrinogen will be measured on citrated plasma by the Clauss clot-based method. Elevated concentrations reflect an acute-phase/inflammatory response; low concentrations may reflect consumption or dilution and a bleeding tendency.

Unit: mg/dL · Reference: 200-400 mg/dL (2-4 g/L)

Baseline (preoperative) and postoperative day 14.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

16 juin 2026

Achèvement primaire (Estimé)

1 mai 2027

Achèvement de l'étude (Estimé)

16 mai 2027

Dates d'inscription aux études

Première soumission

4 juin 2026

Première soumission répondant aux critères de contrôle qualité

3 juillet 2026

Première publication (Réel)

7 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

7 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 juillet 2026

Dernière vérification

1 mars 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner